News | May 30, 2014

Recall Issued for Alere INRatio2 PT/INR Professional Test Strips

Results disagree with confirmed PT/INR reference test results performed by central laboratory

May 30, 2014 — Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor. This recall is expected to cause a shortage of test strips for the Alere INRatio2 professional PT/INR testing. Alere will transition customers from the current Alere INRatio2 PT/INR professional test strip to the Alere INRatio PT/INR test strip, which is not affected by the recall and is used by patient self-testers for home INR monitoring but has also been validated for professional use.

The affected test strips were manufactured from Aug. 22, 2013, through April 2, 2014, and distributed from Aug. 26, 2013, through April 2, 2014.

The Alere lNRatio2 PT/INR monitoring system (professional use) is used for quantitative determination of international normalized ratio (INR) in fresh, capillary whole blood to monitor the effect of warfarin on clotting time (prothrombin time). The system is intended for use outside of the body (in vitro diagnostic use) and not intended to be used for screening purposes. It is also not intended for use in patients who are transitioning from heparin treatment to warfarin therapy.

Initiated in April, the recall is due to complaints of patients who had a therapeutic or near-therapeutic INR result with the Alere INRatio2 PT/INR professional test strip but a significantly higher INR result (outside of therapeutic range) when retesting was performed by a central laboratory because of deterioration in the patient’s clinical condition. Use of this affected product may cause serious adverse health consequences, including death. At the time of writing Alere San Diego received nine reports of malfunctions; six injuries and three deaths caused by bleeding.

On April 17, 2014, Alere sent an Urgent Medical Device Recall letter to all affected customers by fax, email or direct mail. The letter identified the product, problem and the actions to be taken. Customers were requested to complete and sign a Reply Form that was included with the letter. Alere requested the completed form be sent by fax or by email.

For more information: www.inr-care.com

Related Content

Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Overlay Init